The FDA failed to monitor the prescription of a highly potent opioid for years

Thousands of patients were improperly prescribed a highly potent and restricted class of fentanyl, an opioid 100 times more powerful than morphine, between 2012 and 2017, reports CNN.

A paper published by the Journal of the American Medical Association, which was based on nearly 5,000 pages of Food and Drug Administration reports and other documents, described how nearly every party involved in the medical profession — from the FDA and drug companies to doctors and pharmacists — were in part culpable of negligence, allowing the medicine to fall into the wrong hands.

This class of fentanyl is meant only for cancer patients who are experiencing "breakthrough pain" and who have already been prescribed "around-the-clock opioids," writes CNN. Because of its potency, the FDA created a program to monitor prescription of the drug in 2011. The research, however, found that anywhere from 34.6 to 55.4 percent of patients, or about 12,900 people who received the treatments were not, in fact, cancer patients, and were "opioid-nontolerant" or prescribed the drug for conditions such as arthritis. Fentanyl was involved in about 28 percent of drug overdose deaths in 2016, more than any other drug.

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

Join more than 350,000 subscribers and keep yourself informed with a selection of The Week’s most interesting, enlightening and entertaining stories - plus daily puzzles.

Join more than 350,000 subscribers and keep yourself informed with a selection of The Week’s most interesting, enlightening and entertaining stories - plus daily puzzles.

Sign up

"The prescribing of this medicine was supposed to be closely monitored and contained but was not," G. Caleb Alexander, a senior author of the study and director of the Johns Hopkins Bloomberg School of Public Health said, per CNN. "What we found was that several years after the program was started, there were alarming deficiencies identified, and yet little was done by the FDA and drug manufacturers to effectively address these problems."